Zogenix Announces Preliminary, Unaudited Fourth Quarter 2020 Net Product Sales
Total FINTEPLA® preliminary, unaudited net product sales of approximately $8.1 million for the fourth quarter As of December 31, 2020,
Read moreUS98978L2043
The European Commission Approves Zogenix’s FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Dravet Syndrome
Dravet syndrome is a rare, debilitating and difficult-to-treat lifelong epilepsy that begins in infancy EC approval is based on Phase
Read moreZogenix and Leading Experts to Present New Rare Epilepsy Data at AES 2020
New long-term safety, efficacy, and durability data for FINTEPLA® (fenfluramine) oral solution in Dravet syndrome Full results from Phase 3
Read moreZogenix and Leading Experts to Present New Rare Epilepsy Data at AES 2020
New long-term safety, efficacy, and durability data for FINTEPLA® (fenfluramine) oral solution in Dravet syndrome Full results from Phase 3
Read moreZogenix and Leading Experts to Present New Rare Epilepsy Data at AES 2020
New long-term safety, efficacy, and durability data for FINTEPLA® (fenfluramine) oral solution in Dravet syndrome Full results from Phase 3
Read moreZogenix and Leading Experts to Present New Rare Epilepsy Data at AES 2020
New long-term safety, efficacy, and durability data for FINTEPLA® (fenfluramine) oral solution in Dravet syndrome Full results from Phase 3
Read moreZogenix Announces Date Change for Third Quarter 2020 Financial Results and Conference Call and Webcast to November 9
EMERYVILLE, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) — Zogenix, Inc. (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies,
Read moreZogenix to Release Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 10
EMERYVILLE, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) — Zogenix, Inc. (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies,
Read moreZogenix Receives Positive CHMP Opinion for FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Patients with Dravet Syndrome
Dravet syndrome is a rare, life-long, infant- and childhood-onset epilepsy associated with severe, treatment-resistant seizures CHMP positive opinion based on
Read moreZogenix Presents New Data for FINTEPLA® in Dravet Syndrome at CNS 2020
Interim data from open-label extension trial showed substantial seizure reductions were maintained in patients treated with FINTEPLA® for up to
Read more